Table 1.
Demographics and patient disposition
| Parameter | HTX-019 IV push (N = 591) |
|---|---|
| Median age (range), years | 64 (18–94) |
| Sex, n (%) | |
| Male | 272 (46) |
| Female | 319 (54) |
| Race, n (%) | |
| White | 461 (78) |
| African American | 86 (15) |
| Asian | 10 (2) |
| Other | 6 (1) |
| Declined | 23 (4) |
| Patient disposition, n | |
| Total HTX-019 doses | 2066 |
| Median doses per patient | 3 |
| Total chemotherapy doses | 642 |
| Chemotherapy regimens | 76 |
| HEC | 35 |
| MEC | 35 |
| LEC | 6 |
| Patients switching to HTX-019 | 262 |
| Route of HTX-019 administration, n (%) | |
| Central (catheter or PICC) | 511 (86) |
| Peripheral | 80 (14) |
HEC highly emetogenic therapy, IV intravenous, LEC low emetogenic chemotherapy, MEC moderately emetogenic chemotherapy, PICC peripherally inserted central catheter